Comparison of Quantum Dot Biodistribution with a Blood-Flow-Limited Physiologically Based Pharmacokinetic Model

College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina 27606, USA.
Nano Letters (Impact Factor: 13.59). 02/2009; 9(2):794-9. DOI: 10.1021/nl803481q
Source: PubMed

ABSTRACT A physiologically based pharmacokinetic model with partition coefficients estimated from quantum dot (QD) 705 biodistribution was compared with the biodistribution of other QDs in mice and rats to determine the model's predictive ability across QD types, species, and exposure routes. The model predicted the experimentally observed persistence of QDs in tissues but not early time profiles or different QD biodistribution. Therefore, more complex models will be needed to better predict QD biodistribution in vivo.

Download full-text


Available from: Nancy A Monteiro-Riviere, Sep 27, 2015
50 Reads
    • "PBPK models have been commonly developed for drugs to help in the design of therapeutic regimens (Jones et al., 2013; Lin et al., 2015), to aid predictive risk assessment for environmental toxicants (Andersen et al., 1987; Fisher et al., 2011; Lin et al., 2013), as well as to predict drug withdrawal time in food-producing animals (Buur et al., 2008; Leavens et al., 2014). In the field of nanomedicine, researchers have begun to employ PBPK models to simulate the pharmacokinetics of NPs, including quantum dots (Lee et al., 2009; Lin et al., 2008), carbon (Pery et al., 2009), silver (Bachler et al., 2013; Lankveld et al., 2010), titanium dioxide (Bachler et al., 2014), polyacrylamide (Li et al., 2014), poly(lactic-co-glycolic) acid (Li et al., 2012) NPs, and gold/dendrimer composite nanodevices (Mager et al., 2012). These models greatly improve our understanding of the pharmacokinetics of NPs; some of these models have been extrapolated to humans and proved to be helpful in risk assessment (Bachler et al., 2013, 2014). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nanoparticles (NPs) are widely used in various fields of nanomedicine. A systematic understanding of NP pharmacokinetics is crucial in their design, applications, and risk assessment. In order to integrate available experimental information and to gain insights into NP pharmacokinetics, a membrane-limited physiologically based pharmacokinetic (PBPK) model for polyethylene glycol-coated gold (Au) NPs (PEG-coated AuNPs) was developed in mice. The model described endocytosis of the NPs in the liver, spleen, kidneys, and lungs and was calibrated using data from mice that were intravenously injected with 0.85 mg/kg 13 nm and 100 nm PEG-coated AuNPs. The model adequately predicted multiple external datasets for PEG-coated AuNPs of similar sizes (13-20 nm; 80-100 nm), indicating reliable predictive capability in suitable size ranges. Simulation results suggest that endocytosis of NPs is time and size dependent, i.e. endocytosis of larger NPs occurs immediately and predominately from the blood, whereas smaller NPs can diffuse through the capillary wall and their endocytosis appears mainly from the tissue with a 10-h delay, which may be the primary mechanism responsible for the reported size-dependent pharmacokinetics of NPs. Several physiological parameters (e.g. liver weight fraction of body weight) were identified to have a high influence on selected key dose metrics, indicating the need for additional interspecies comparison and scaling studies and to conduct pharmacokinetic studies of NPs in species that are more closely related to humans in these parameters. This PBPK model provides useful insights into the size, time, and species dependence of NP pharmacokinetics.
    Nanotoxicology 05/2015; DOI:10.3109/17435390.2015.1027314 · 6.41 Impact Factor
  • Source
    • "One of the issues in the development of the models is the need to accurately describe the distribution of the nanoparticles in the tissues, as the blood-flow limited model most commonly used for chemicals (International Programme on Chemical Safety, 2010) will not be appropriate for nanoparticles [5] [6]. Although intraventricular delivery of drugs to the CSF is known to result in greater drug concentration with a longer halflife in the CSF, drug penetration in the parenchyma is limited, with most of the drug being taken up by the ependymal cells lining the ventricles rather than the target cells [7] [8]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nanotechnology offers a new platform for therapeutic delivery of antiretrovirals to the central nervous system (CNS). Nanoformulated antiretroviral drugs offer multifunctionality, that is, the ability to package multiple diagnostic and therapeutic agents in the same nanocompose, along with the added provisions of site-directed delivery, delivery across the blood-brain-barrier (BBB), and controlled release of therapeutics. We studied the viability of dendrimers and dendriplexes in human primary astrocytes, as well as their uptake by these astrocytes. Functional validation was performed by using specific siRNA against HIV-1 Nef to interfere to HIV-1 infectivity. A high efficiency in Nef silencing, reducing HIV-1 infectivity was observed in astrocytes treated with dendriplexes compared with control or siRandom treated astrocytes. More interestingly, we studied the biodistribution of the second generation of carbosilane dendrimer loaded with FITC (2G-(SNMe3I)11-FITC) in vivo, in BALB/c mice. Dendriplexes were inoculated into BALB/c mice by the retro-orbital venous plexus, and their localization was determined after 1 and 24h post-injection. Dendriplexes were detected inside the brain by a sensitive imaging system of fluorescent imaging in vivo (IVIS Lumina), and by confocal microscopy analysis of sections of OCT-embedded tissues. The 2G-(SNMe3I)11-FITC dendrimer transported efficiently siRNA into the brain, crossing the BBB. Moreover, this dendrimer successfully delivered and transfected siRNA to HIV-infected human primary astrocytes and achieved gene silencing without causing cytotoxicity. These results highlight the potential of this nanoformulation in the treatment of neurological disorders. Copyright © 2014. Published by Elsevier B.V.
    Journal of Controlled Release 01/2015; 200. DOI:10.1016/j.jconrel.2014.12.042 · 7.71 Impact Factor
  • Source
    • "Since the early 1990s, PBPK models had been developed for five potentially toxic metals: arsenic, chromium, lead, nickel, and zinc.23 More recently, PBPK models for NPs have been published for carbon,24 poly(lactic-co-glycolic) acid (PLGA),25 silver,26 and quantum dots.27 However, with the exception of the model for PLGA NPs, no PBPK model could successfully be validated against independent data. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Silver is a strong antibiotic that is increasingly incorporated into consumer products as a bulk, salt, or nanosilver, thus potentially causing side-effects related to human exposure. However, the fate and behavior of (nano)silver in the human body is presently not well understood. In order to aggregate the existing experimental information, a physiologically based pharmacokinetic model (PBPK) was developed in this study for ionic silver and nanosilver. The structure of the model was established on the basis of toxicokinetic data from intravenous studies. The number of calibrated parameters was minimized in order to enhance the predictive capability of the model. We validated the model structure for both silver forms by reproducing exposure conditions (dermal, oral, and inhalation) of in vivo experiments and comparing simulated and experimentally assessed organ concentrations. Therefore, the percutaneous, intestinal, or pulmonary absorption fraction was estimated based on the blood silver concentration of the respective experimental data set. In all of the cases examined, the model could successfully predict the biodistribution of ionic silver and 15-150 nm silver nanoparticles, which were not coated with substances designed to prolong the circulatory time (eg, polyethylene glycol). Furthermore, the results of our model indicate that: (1) within the application domain of our model, the particle size and coating had a minor influence on the biodistribution; (2) in vivo, it is more likely that silver nanoparticles are directly stored as insoluble salt particles than dissolve into Ag(+); and (3) compartments of the mononuclear phagocytic system play a minor role in exposure levels that are relevant for human consumers. We also give an example of how the model can be used in exposure and risk assessments based on five different exposure scenarios, namely dietary intake, use of three separate consumer products, and occupational exposure.
    International Journal of Nanomedicine 09/2013; 8:3365-82. DOI:10.2147/IJN.S46624 · 4.38 Impact Factor
Show more